Udit Batra: Yes. I mean €“ and with such a significant service team around the globe, slightly shy of 2,000 people, we believe that there is a significant opportunity to increase the service attachment rates. And in addition, about 1,400 to 1,500 sales, field sales representatives should help us increase penetration of light scattering. And Geof is smiling, as I say that, light scattering is deeper into our collective customer segments. So extremely, extremely excited about the opportunity there. But as Amol said, we think of instruments as recurring just as much as we think of service and consumables. They just recur over a longer time frame. And if you’re disciplined, you can make sure that they are.
Operator: The next question is coming from Patrick Donnelly of Citi. Your line is open.
Patrick Donnelly: Hey guys, thank you for taking the questions. Udit, maybe one on the industrial piece, that put up pretty nice growth in the quarter, I think, in the mid-teens. Can you just talk about what you’re seeing there? I mean, I know in the past quarters, you talked a little bit about PFAs testing, environmental being nice tailwinds. So, maybe just talk to what you’re hearing from the customer base their expectations into 2023. Thanks.
Udit Batra: Sure. So thanks for the question, Patrick. Industrial for the year just on the fact, I mean, grew 15%. And we saw nice high teens in the U.S., mid-teens in Europe, China, high single digit to low teens despite the lockdowns. And industrial across the board, right, so applications in food testing with the Xevo TQ Absolute, with PFAs testing was excellent. The PA business with battery testing, especially with the introduction of our new , we see incredible opportunity there to increase penetration of our existing instruments, and that’s been going extremely well. And electronics, electronic chemicals testing has also been doing extremely well in the TA business, which has been in the high teens in the Industrial segment.
So industrial, across all regions, across the food and environmental segments, as well as materials segment has been doing extremely well. So, I hope that gives you color on how we explained the results so far. Going forward, with the new products, there is a lot more runway for Xevo TQ Absolute and PFAs applications. We intend, of course, to take that instrument into the pharma space. We think there’s incredible opportunity. For TA, we are seeing really, really good traction of our products in the battery testing value chain, all the way from raw materials to process development, not unlike bioprocessing, to now establishing online, at-line testing with our instruments for several of our customers. So, also going forward, a really healthy outlook.
And I think the only prudence that we, sort of built-in is with what we expect in China, like China is a pretty strong grower in that segment as well, and we want to make sure that we get more data before we start reaching out more.
Operator: The next question is coming from Puneet Souda, SVB Securities. Your line is open.
Puneet Souda : Yes. Hi, Udit and Geoff, congrats on this acquisition. It’s great to see a light scattering outlook going into QA/QC. So, maybe my first question there is, when we look at the downstream QA/QC and late stages, when you look at the synergies, is that sort of the time line you’re thinking about moving light scattering into a number of these applications? And, Udit, could you maybe elaborate what is needed to integrate MALS into Empower? And what’s the, sort of the outlook for Empower potentially becoming, sort of the backbone for biomolecules with BioAccord and light scattering? And last one, if I could squeeze in, any thoughts on the China loan stimulus benefit for 2023? Thank you.
